-
A5394: Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg
Open and enrolling
Hepatitis
-
A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy
“Safety and Immunotherapeutic Activity of Cemiplimab in Participants with HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose…
Active, Not Recruiting
Hepatitis
Participants will be on study for up to 90 weeks (78 weeks following the last study drug infusion) with frequent safety evaluations.
-
This is a study to treat participants, with or without HIV, who are found to have been recently infected with…
Closed to accrual
Hepatitis
Up to 28 weeks on Step 1 and up to an additional 40 weeks if on Step 2.
-
A5379 is a study looking at hepatitis B vaccination in adults living with HIV. Hepatitis B is a serious viral…
Closed to accrual
Hepatitis
72 weeks
